[Changes of plasma ribonuclease activities according to the method of treatment in gynecologic cancer patients (author's transl)].
Plasma RNase activity was studied in normal and females with gynecological malignancies. Basic experimental data of RNase showed linear regression to the incubation period up to 20 min., optimal pH at 8.0, maximal absorption at 260 nm and sufficient substrate concentration with 120 microgram/0.02 ml. Coefficient of variation was 6.2% (n = 15) intra-assay study. Mean plasma RNase of 32 normal subjects was 0.24 +/- 0.04 (mean +/- SD) delta OD/0.01 ml/20 min. Values deviating mean + 2SD (0.32) were regarded as abnormal. Mean value at pre-treatment was 0.27 +/- 0.04 for benign tumor and abnormal value rate was 11% (2/19). The values in cervical cancer patients were 0.29 +/- 0.06 [91.7% (11/12)] for recurrent cases. The values and abnormal rates raised as clinical stage advanced. The values were also high in advanced ovarian and endometrial cancer patients. It came into normal range with the complete surgery in early stage. Pre- and post-treatment RNase value were analysed on 29 advanced cervical, endometrial and ovarian cancer patients. Abnormal value rate was lowered from 60% (9/15) to 26.6% (4/15) in therapy-responding group, but were kept high in 14 therapy-resistant group. The value was raised again as the disease recurred. Evaluation of plasma RNase value is useful means in biochemical diagnosis and in prognosing gynecological malignancies.
D002294:Carcinoma, Squamous Cell / Q000201:enzymology; D005260:Female; D006801:Humans; D007889:Leiomyoma / Q000201:enzymology; D009364:Neoplasm Recurrence, Local; D010051:Ovarian Neoplasms / Q000201:enzymology*; D012260:Ribonucleases / Q000097:blood*; D002583:Uterine Cervical Neoplasms / Q000201:enzymology; D014594:Uterine Neoplasms / Q000201:enzymology*
D012260:Ribonucleases